These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10803764)

  • 21. The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients.
    Berns JS; Fishbane S; Elzein H; Lynn RI; Deoreo PB; Tharpe DL; Meisels IS
    Hemodial Int; 2005 Jul; 9(3):255-63. PubMed ID: 16191075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.
    Moran LJ; Carey P; Johnson CA
    Am J Hosp Pharm; 1992 Jun; 49(6):1451-4. PubMed ID: 1529988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and long-term significance of transient ST segment deviation in hemodialysis patients.
    Conlon PJ; Krucoff MW; Minda S; Schumm D; Schwab SJ
    Clin Nephrol; 1998 Apr; 49(4):236-9. PubMed ID: 9582554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit.
    To LL; Stoner CP; Stolley SN; Buenviaje JD; Ziegler TW
    Am J Health Syst Pharm; 2001 Nov; 58(21):2061-5. PubMed ID: 11715828
    [No Abstract]   [Full Text] [Related]  

  • 25. Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness.
    Eschbach JW
    J Am Soc Nephrol; 2002 May; 13(5):1412-4. PubMed ID: 11961032
    [No Abstract]   [Full Text] [Related]  

  • 26. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
    Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
    Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients.
    Abu-Alfa AK; Cruz D; Perazella MA; Mahnensmith RL; Simon D; Bia MJ
    Am J Kidney Dis; 2000 Jun; 35(6):1076-82. PubMed ID: 10845820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
    Grabe DW
    Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Should the hematocrit (hemoglobin) be normalized in Pre-ESRD or dialysis patients? Yes!
    Besarab A; Aslam M
    Blood Purif; 2001; 19(2):168-74. PubMed ID: 11150804
    [No Abstract]   [Full Text] [Related]  

  • 30. Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis.
    Goodkin DA; Gimenez LF; Graber SE; Van Stone JC; Egrie JC; Okamoto DM
    Clin Nephrol; 1999 Jun; 51(6):367-72. PubMed ID: 10404697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
    Thanakitcharu P; Siriwiwatanakul N
    J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential angiotensin-converting enzyme inhibitor-epoetin alfa interaction in patients receiving chronic hemodialysis.
    Schwenk MH; Jumani AQ; Rosenberg CR; Kulogowski JE; Charytan C; Spinowitz BS
    Pharmacotherapy; 1998; 18(3):627-30. PubMed ID: 9620114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.
    Weir MR; Pergola PE; Agarwal R; Fink JC; Kopyt NP; Singh AK; Kumar J; Schmitt S; Schaffar G; Rudy A; McKay JP; Kanceva R
    Am J Nephrol; 2017; 46(5):364-370. PubMed ID: 29084409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The new rHuEPO alpha (epotin) in the management of anemia of end-stage renal disease in patients on maintenance hemodialysis.
    Abbas EE; Afioni N; Al Wakeel J; Bakr MA; Dham R; Donia A; Droubi N; Khidir E; Mathew CM; Mitwali AH; Naga S; Pingle A; Rashed A; Roshdy A; Shaheen F; Shaibani B; Shaibani FM; Shaker DS; Sheiban A; Solieman M
    Transplant Proc; 2004; 36(6):1805-11. PubMed ID: 15350482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia.
    Baldamus C; Krivoshiev S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A
    Adv Ther; 2008 Nov; 25(11):1215-28. PubMed ID: 18931828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial.
    Keown PA; Churchill DN; Poulin-Costello M; Lei L; Gantotti S; Agodoa I; Gitlin M; Gandra SR; Mayne TJ
    Hemodial Int; 2010 Apr; 14(2):168-73. PubMed ID: 20345390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erythropoietin and iron use in peritoneal dialysis patients. Report from the 1997 HCFA end-stage renal disease core indicators project.
    Bailie GR; Frankenfield DL; Prowant BF; McClellan W; Rocco MV
    Am J Kidney Dis; 1999 Jun; 33(6):1187-9. PubMed ID: 10352214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease.
    Berns JS; Rudnick MR; Cohen RM; Bower JD; Wood BC
    Kidney Int; 1999 Jul; 56(1):253-60. PubMed ID: 10411700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.